ASGR2: A Potential Drug Target and Biomarker (G433)

Target Name: ASGR2

NCBI ID: G433

ASGR2

ASGR2: A Potential Drug Target and Biomarker

Autophagy is a crucial regulatory process in eukaryotic cells that plays a vital role in cell survival and homeostasis. However, when the process goes awry, it can lead to a range of diseases, including neurodegenerative disorders, cancer, and autoimmune diseases. The aspartate-specific G protein-coupled receptor 2 (ASGR2) is a protein that has been identified as a potential drug target and biomarker for several diseases.

ASGR2 is a member of the G protein-coupled receptor family, which includes over 700 different proteins that play a critical role in cellular signaling. G protein-coupled receptors are transmembrane proteins that interact with intracellular signaling molecules, such as GTP, to regulate various cellular processes, including intracellular signaling, cell adhesion, and neurotransmission.

ASGR2 is expressed in many different tissues and cells throughout the body, including the brain, pancreas, and gastrointestinal tract. It has been shown to play a role in various physiological processes, including cell survival, growth, and angiogenesis.

ASGR2 has also been implicated in several diseases, including neurodegenerative disorders, cancer, and autoimmune diseases. For example, studies have shown that ASGR2 is overexpressed in the brains of individuals with Alzheimer's disease, and that it is involved in the development of neurofibrillary tangles and beta-amyloid plaques, which are hallmark features of Alzheimer's disease.

In addition to its role in disease, ASGR2 has also been identified as a potential drug target. Researchers have shown that ASGR2 can be targeted with small molecules, such as inhibitors, to selectively modulate its activity. This has led to a growing interest in ASGR2 as a drug target for a variety of diseases, including neurodegenerative disorders, cancer, and autoimmune diseases.

ASGR2 has also been shown to be a potential biomarker for several diseases. For example, studies have shown that ASGR2 levels are elevated in the brains of individuals with Alzheimer's disease, and that they are associated with poor clinical outcome in individuals with neurodegenerative disorders. In addition, ASGR2 has been shown to be elevated in the blood samples of individuals with pancreatic cancer, and that it is associated with poor prognosis in these individuals.

In conclusion, ASGR2 is a protein that has been identified as a potential drug target and biomarker for several diseases. Its role in the regulation of cellular processes and its involvement in several diseases make it an attractive target for small molecule inhibitors. Further research is needed to fully understand the role of ASGR2 in disease and to develop safe and effective drugs that can target it.

Protein Name: Asialoglycoprotein Receptor 2

Functions: Mediates the endocytosis of plasma glycoproteins to which the terminal sialic acid residue on their complex carbohydrate moieties has been removed. The receptor recognizes terminal galactose and N-acetylgalactosamine units. After ligand binding to the receptor, the resulting complex is internalized and transported to a sorting organelle, where receptor and ligand are disassociated. The receptor then returns to the cell membrane surface

The "ASGR2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ASGR2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets